TY - JOUR T1 - Evaluation of Bcl-2 Expression in Aggressive and Non-aggressive Basal Cell Carcinomas TT - بررسی تظاهر 2-bcl در انواع مهاجم و غیرمهاجم بازال سل کارسینوما JF - RJMS JO - RJMS VL - 11 IS - 40 UR - http://rjms.iums.ac.ir/article-1-9-en.html Y1 - 2004 SP - 239 EP - 245 KW - Key Words: 1) Bcl-2 2) BCC 3) Oncogene 4) Apoptosis N2 - Bcl-2, a well-known anti-apoptotic gene, promotes cell viability without cell proliferation. Expression of the bcl-2 oncogene is reported in certain low grade neoplasms including Basal Cell Carcinomas(BCCs). Bcl-2 expression in BCCs is contradictory, with 67-100% immunopositivity being reported. The purpose of this study was to evaluate bcl-2 expression in the indolent variants of BCC, namely superficial and circumscribed subtypes and their aggressive counterparts infiltrative and morphea-like subtypes. Anti-human bcl-2 monoclonal antibody was used to identify its protein product in formalin-fixed tissue from 33 BCCs. 22 histophathologically non-aggressive and 11 aggressive subtypes were investigated. Quantity of decoration of tumor cells for bcl-2 was graded in the following fashion: 0 to 25%, 26% to 50%, 51% to 75%, 76% to 100%. Intensity of decoration was evaluated as slight, moderate and intense. Bcl-2 expression was observed in all of the BCCs, but high bcl-2 expression was statistically a significant feature of non-aggressive BCCs(P=0.001). Different bcl-2 expression in various non-aggressive and aggressive histopathological subtypes of BCCs suggests that despite the common derivation of these tumors from a primitive basaloid stem cell and a limited potential for metastasis, they form a heterogeneous group of tumors. While the superficial and circumscribed BCCs are indolent slow-growing tumors with high bcl-2 labeling, the aggressive BCCs are infiltrative and morphea-like tumors with low bcl-2 labeling. High expression of bcl-2 may indicate a more favorable prognosis in BCCs. M3 ER -